Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) | RFA AR 20 002

Opportunity Information: Apply for RFA AR 20 002

The National Institutes of Health (NIH), through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), offered the grant opportunity "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)" under funding opportunity number RFA-AR-20-002 (CFDA 93.846). It is a discretionary NIH grant using the R21 mechanism, which is typically intended to support exploratory, developmental, and high-impact projects that can be completed with limited funds and within a relatively short period. The emphasis in this announcement is on mechanistic ancillary studies that are time-sensitive and that can be carried out alongside an existing, actively running clinical project rather than starting a new standalone clinical effort.

The central purpose of the FOA is to help investigators leverage already-funded and already-operational clinical projects (the "parent" projects) to answer additional mechanistic questions aligned with the NIAMS mission. The parent project can be an interventional clinical trial or a non-interventional clinical study such as an observational cohort, as long as it is actively collecting clinical data and/or patient samples. The key idea is that the parent study already has what many new studies struggle to build from scratch: a well-characterized patient cohort, established recruitment and follow-up procedures, clinical infrastructure, curated datasets, and access to biospecimens. The ancillary study then "plugs into" that framework to extract more scientific value, for example by adding specialized assays, biomarker analyses, immunologic or molecular profiling, or other mechanistic measurements that deepen understanding of disease biology.

A defining feature of this opportunity is speed and practicality. NIAMS designed it for situations where a mechanistic add-on needs to happen while the parent study is underway, meaning the timing matters because samples are being collected now, participants are being seen now, and the window to capture certain biological signals or clinical states may be limited. To support that urgency, applications are intended to move through an accelerated review and award process compared with typical grant cycles. In effect, the FOA acts as a flexible mechanism to maximize the return on existing investments by enhancing the scientific content and long-term value of clinical projects that are already funded by public or private sources.

The research scope is explicitly mechanistic and tied to NIAMS-relevant diseases and organ systems, which generally include arthritis and rheumatic diseases, musculoskeletal and bone disorders, and skin biology and skin diseases. The FOA frames the expected impact in terms of improving the research community's understanding of underlying disease processes and potentially identifying novel targets for diagnosis, treatment, or prevention. Importantly, despite being linked to clinical projects, the FOA is labeled "Clinical Trial Not Allowed," meaning the funded R21 ancillary work should not itself constitute a new clinical trial. In practical terms, that typically means the ancillary project should not introduce a new prospective intervention with health-related outcomes as its primary purpose; instead, it should focus on mechanistic measurements and analyses that complement what the parent project is already doing.

In terms of funding details, the award ceiling listed for this opportunity is $250,000, consistent with the smaller, exploratory nature of R21 awards. The original closing date shown in the source information is 2020-12-01, and the FOA was created on 2019-04-25. While the number of expected awards is not specified in the provided source, the overall structure suggests NIAMS intended to support a set of add-on mechanistic projects that can be executed efficiently because they rely on existing cohorts, workflows, and sample pipelines.

Eligibility is broad and includes many types of domestic U.S. organizations and governments. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (as long as they are not institutions of higher education in those categories); for-profit organizations other than small businesses; and small businesses. The FOA also calls out additional eligible applicant categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving Institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.

The non-U.S. eligibility rules are more restrictive. Non-domestic (non-U.S.) entities or foreign institutions are not eligible to apply directly, and non-domestic components of U.S. organizations are also not eligible to apply. However, "foreign components" as defined in the NIH Grants Policy Statement are allowed, which generally means a U.S. applicant organization may include certain elements of the project that involve foreign collaborators, foreign performance sites, or foreign resources when well-justified and compliant with NIH policy. This distinction matters: the applicant organization must be eligible and typically U.S.-based, but specific foreign involvement can be permitted under NIH rules when it strengthens the science.

Overall, the opportunity is designed for investigators who already have access to an ongoing clinical study or trial and can make a strong case that a targeted, mechanistic add-on will significantly increase the scientific yield of that parent project. The most competitive ancillary proposals under this kind of FOA are usually those that (1) clearly justify why the work must be done now while the parent study is active, (2) demonstrate concrete access to participants, samples, and data through the parent project, (3) propose mechanistic endpoints and analyses that are feasible within the R21 budget and timeline, and (4) show how the findings will meaningfully advance NIAMS-relevant biology and open paths toward improved diagnosis, treatment, or prevention.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
• This funding opportunity was created on 2019-04-25.
• Applicants must submit their applications by 2020-12-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $250,000.00 in funding.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AR 20 002

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: